GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD)
United States Tim Bateman Francois Tranquart Centers For Disease Radiologic Imaging Program At Saint Luke Hospital Lantheus Holdings Inc
Source: dicardiology.com